JP2022508203A5 - - Google Patents
Info
- Publication number
- JP2022508203A5 JP2022508203A5 JP2021529110A JP2021529110A JP2022508203A5 JP 2022508203 A5 JP2022508203 A5 JP 2022508203A5 JP 2021529110 A JP2021529110 A JP 2021529110A JP 2021529110 A JP2021529110 A JP 2021529110A JP 2022508203 A5 JP2022508203 A5 JP 2022508203A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- saturated
- halogen
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018117047 | 2018-11-22 | ||
| CNPCT/CN2018/117047 | 2018-11-22 | ||
| PCT/CN2019/119373 WO2020103815A1 (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508203A JP2022508203A (ja) | 2022-01-19 |
| JP2022508203A5 true JP2022508203A5 (enExample) | 2022-11-24 |
| JP7664156B2 JP7664156B2 (ja) | 2025-04-17 |
Family
ID=70774321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529110A Active JP7664156B2 (ja) | 2018-11-22 | 2019-11-19 | Ｇｌｐ－１ｒアゴニスト及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US12365670B2 (enExample) |
| EP (1) | EP3883928B1 (enExample) |
| JP (1) | JP7664156B2 (enExample) |
| KR (1) | KR102904955B1 (enExample) |
| CN (1) | CN113227068B (enExample) |
| AU (1) | AU2019382642B2 (enExample) |
| BR (1) | BR112021009877A2 (enExample) |
| CA (1) | CA3120499A1 (enExample) |
| CL (1) | CL2021001332A1 (enExample) |
| CO (1) | CO2021008089A2 (enExample) |
| CR (1) | CR20210341A (enExample) |
| CU (1) | CU20210042A7 (enExample) |
| EA (1) | EA202191432A1 (enExample) |
| IL (1) | IL283322B2 (enExample) |
| MA (1) | MA54555A (enExample) |
| MX (1) | MX2021006034A (enExample) |
| PE (1) | PE20211871A1 (enExample) |
| PH (1) | PH12021551165A1 (enExample) |
| SA (1) | SA521422068B1 (enExample) |
| SG (1) | SG11202105241YA (enExample) |
| TW (1) | TWI839416B (enExample) |
| UA (1) | UA130273C2 (enExample) |
| WO (1) | WO2020103815A1 (enExample) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| MY210507A (en) | 2018-08-13 | 2025-09-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| PH12022550339A1 (en) | 2019-09-12 | 2023-03-13 | Hoffmann La Roche | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| ES3029360T3 (en) * | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN115697999A (zh) * | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PT4157832T (pt) * | 2020-05-27 | 2024-07-30 | Qilu Regor Therapeutics Inc | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos |
| PH12022553313A1 (en) * | 2020-06-04 | 2023-04-12 | Hangzhou Sciwind Biosciences Co Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| US12637474B2 (en) | 2020-06-04 | 2026-05-26 | Hangzhou Sciwind Biosciences Co., Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| CN117645601A (zh) * | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| TW202214622A (zh) * | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ－１ｒ促效劑及其用途 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538408A (ja) * | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒ作動薬としての化合物 |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| US12552808B2 (en) | 2020-09-03 | 2026-02-17 | Amgen Inc. | Diol desymmetrization by nucleophilic aromatic substitution |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115515956B (zh) * | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116348464B (zh) * | 2020-10-12 | 2026-06-16 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022078380A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US12516041B2 (en) | 2020-10-14 | 2026-01-06 | Qilu Regor Therapeutics Inc. | Crystal forms of GLP-1R agonists and uses thereof |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN114591308B (zh) * | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| KR20230124956A (ko) * | 2020-12-25 | 2023-08-28 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 5원 고리 유도체 및 이의 의학적 용도 |
| CN117043154A (zh) * | 2021-01-28 | 2023-11-10 | 卡莫特医疗有限公司 | Gpcr受体激动剂、包含其的药物组合物以及它们的使用方法 |
| US20240252492A1 (en) * | 2021-01-28 | 2024-08-01 | Carmot Therapeutics ,Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| CN114907351A (zh) * | 2021-02-07 | 2022-08-16 | 杭州中美华东制药有限公司 | 三环类glp-1受体激动剂及其用途 |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN116940561B (zh) * | 2021-03-22 | 2026-08-11 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| CA3217720A1 (en) * | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN117098758A (zh) | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| US20240382471A1 (en) * | 2021-07-21 | 2024-11-21 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| US20240360109A1 (en) * | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| TWI843243B (zh) * | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| CN115850296B (zh) * | 2021-12-03 | 2025-03-11 | 杭州先为达生物科技股份有限公司 | 一种噻吩并咪唑类化合物的晶型及其制备方法 |
| CN114163438A (zh) * | 2021-12-13 | 2022-03-11 | 无锡捷化医药科技有限公司 | 一种2-甲基-3-羰基吡唑并[4,3-c]吡啶-7-羧酸盐酸盐的制备方法 |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| DK4455141T3 (da) * | 2021-12-23 | 2026-04-27 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| CN118613476A (zh) * | 2022-01-10 | 2024-09-06 | 西藏海思科制药有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
| JP2025506474A (ja) * | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| AU2023232184A1 (en) | 2022-03-08 | 2024-09-26 | Guangzhou Apichope Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| EP4490155A1 (en) * | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250250269A1 (en) * | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN116574092B (zh) * | 2022-05-20 | 2024-08-20 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| IL318410A (en) * | 2022-07-18 | 2025-03-01 | Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd | Polymorphic form of GLP-1R agonist, method of preparation thereof and use thereof |
| CN119923395A (zh) * | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| JP2025530809A (ja) * | 2022-09-06 | 2025-09-17 | 徳睿智薬（蘇州）新薬研発有限公司 | Ｇｌｐ－１ｒアゴニスト化合物の結晶多形物及びその製造方法と使用 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| CN116102543B (zh) * | 2022-10-21 | 2025-07-22 | 江南大学 | 一种glp-1r激动剂、合成方法及其用途 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| JP2026501161A (ja) * | 2022-12-13 | 2026-01-14 | 杭州中美華東製薬有限公司 | Ｇｌｐ－１受容体作動薬の新規結晶形、その製造方法、その医薬組成物およびその使用 |
| AU2023394509A1 (en) * | 2022-12-13 | 2025-07-10 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| US20260217707A1 (en) * | 2023-01-17 | 2026-07-30 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| KR20250139383A (ko) * | 2023-02-02 | 2025-09-23 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 시클로알켄계 화합물의 염, 결정형 및 이의 제조 방법과 응용 |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| CN121866253A (zh) * | 2023-07-04 | 2026-04-14 | 杭州中美华东制药有限公司 | 一种glp1r激动剂及其中间体的制备方法 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| KR20260038229A (ko) * | 2024-09-11 | 2026-03-18 | 한미약품 주식회사 | Glp-1 수용체 작용제 및 이의 용도 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| CA2523743A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| AU2005283326B2 (en) | 2004-09-13 | 2011-07-21 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| EP1844043A2 (en) | 2004-11-18 | 2007-10-17 | The Institutes for Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| US20070238669A1 (en) | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
| CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| WO2011156655A2 (en) | 2010-06-09 | 2011-12-15 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN104080767A (zh) * | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| CA2978823C (en) | 2014-12-29 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| JP7161605B2 (ja) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4069686B1 (en) | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| CA3163979A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN115697999A (zh) | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| MX2022010811A (es) | 2020-03-27 | 2022-09-27 | Pfizer | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. |
| EP4130005A4 (en) | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| CN115315426B (zh) | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| PT4157832T (pt) * | 2020-05-27 | 2024-07-30 | Qilu Regor Therapeutics Inc | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos |
-
2019
- 2019-11-19 EA EA202191432A patent/EA202191432A1/ru unknown
- 2019-11-19 JP JP2021529110A patent/JP7664156B2/ja active Active
- 2019-11-19 US US17/296,078 patent/US12365670B2/en active Active
- 2019-11-19 CA CA3120499A patent/CA3120499A1/en active Pending
- 2019-11-19 CR CR20210341A patent/CR20210341A/es unknown
- 2019-11-19 EP EP19887901.7A patent/EP3883928B1/en active Active
- 2019-11-19 MA MA054555A patent/MA54555A/fr unknown
- 2019-11-19 CU CU2021000042A patent/CU20210042A7/es unknown
- 2019-11-19 PE PE2021000746A patent/PE20211871A1/es unknown
- 2019-11-19 IL IL283322A patent/IL283322B2/en unknown
- 2019-11-19 WO PCT/CN2019/119373 patent/WO2020103815A1/en not_active Ceased
- 2019-11-19 KR KR1020217019126A patent/KR102904955B1/ko active Active
- 2019-11-19 UA UAA202103473A patent/UA130273C2/uk unknown
- 2019-11-19 SG SG11202105241YA patent/SG11202105241YA/en unknown
- 2019-11-19 MX MX2021006034A patent/MX2021006034A/es unknown
- 2019-11-19 CN CN201980087385.0A patent/CN113227068B/zh active Active
- 2019-11-19 BR BR112021009877-1A patent/BR112021009877A2/pt unknown
- 2019-11-19 AU AU2019382642A patent/AU2019382642B2/en active Active
- 2019-11-22 TW TW108142555A patent/TWI839416B/zh active
-
2020
- 2020-05-15 US US16/874,908 patent/US10844049B2/en active Active
-
2021
- 2021-05-20 SA SA521422068A patent/SA521422068B1/ar unknown
- 2021-05-20 CL CL2021001332A patent/CL2021001332A1/es unknown
- 2021-05-21 PH PH12021551165A patent/PH12021551165A1/en unknown
- 2021-06-21 CO CONC2021/0008089A patent/CO2021008089A2/es unknown
-
2025
- 2025-07-14 US US19/268,583 patent/US20260035362A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4157832T3 (fi) | Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia | |
| JP2021091683A5 (enExample) | ||
| JP5305421B2 (ja) | ジアミン誘導体の製造方法 | |
| JP2019203015A5 (enExample) | ||
| FI4058445T3 (fi) | Glp-1-reseptoriagonisti ja sen käyttö | |
| JP2019069940A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2017504640A5 (enExample) | ||
| RU2008123055A (ru) | СОЛИ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ | |
| JP2006525359A5 (enExample) | ||
| MXPA03006748A (es) | 1, 2, 3, 4-tetrahidronaftil aminas aciladas y su uso como farmaceuticos. | |
| JP2023546125A5 (enExample) | ||
| JP2011513367A5 (enExample) | ||
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| IL287159B2 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| JP2021522262A5 (enExample) | ||
| JP2023550444A5 (enExample) | ||
| JP2010532386A5 (enExample) | ||
| AR075609A1 (es) | Derivados pirazolicos heterociclicos nitrogenados activadores de guanilatociclasas solubles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares, entre otras. | |
| JP2004502756A5 (enExample) | ||
| JP2015533168A5 (enExample) | ||
| JP2024513227A5 (enExample) | ||
| JP2010516702A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2024534781A5 (enExample) | ||
| JP2008537547A5 (enExample) |